Generex granted U.S. patent covering broad claims for drug delivery via the buccal cavity

By Lisa Kerner

Charlotte, N.C., Aug. 16 - The U.S. Patent and Trademark Office granted a patent to Generex Biotechnology Corp. covering broad claims for the delivery of macromolecules via the buccal cavity of the mouth.

Entitled "Methods of Administering and Enhancing Absorption of Pharmaceutical Agents," the patent relates to the company's process to produce safe and effective oral formulations that result in increased bioavailability of the active drug and more rapid onset of action.

"This important new patent will augment the protection of our proprietary RapidMist drug delivery technologies," chief operating officer Rose Perri said in a company news release.

The patent also provides broad intellectual property protection for the company's flagship product, Generex Oral-lyn oral insulin spray, officials said.

Toronto-based Generex develops drug delivery systems and technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.